1.17 USD
↘ 0.04 (3.31%)AT CLOSE (11:59 AM EDT)
Geron Corp
GERNNASDAQ • USD
1.17
↗ 0.01 (0.43%)
POST MARKET (AS OF 07:46 PM EDT)
Post Market
AS OF 07:46 PM EDT
1.17
↗ 0.01 (0.43%)
Market: CLOSED
Open?$1.21
High?$1.21
Low?$1.16
Prev. Close?$1.21
Volume?9.6M
Avg. Volume?13.3M
VWAP?$1.18
Rel. Volume?0.72x
Bid / Ask
Bid?$1.17 × 1.0K
Ask?$1.18 × 2.0K
Spread?$0.01
Midpoint?$1.17
Valuation & Ratios
Market Cap?750.6M
Shares Out?641.5M
Float?625.8M
Float %?97.6%
P/E Ratio?N/A
P/B Ratio?3.28
EPS?-$0.10
Dividend?0.00%
Ex-Dividend?N/A
Geron Corp (GERN) trades at $1.17 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place GERN at a fair price relative to peers.
Technical & fundamental data as of Jun 5, 2026.
RelatedALKS
News
Profile
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Themes
Address
919 EAST HILLSDALE BOULEVARD
FOSTER CITY, CA 94404
Phone: (650) 473-7700
FOSTER CITY, CA 94404
Phone: (650) 473-7700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?62
Short Sent.?65
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.40Distress
Confidence?57%Low
Short InterestHigh
Short % of Float?11.21%High
Short Interest?70.2M
Days to Cover?3.8
Free Float625.8M
Avg Daily Volume18.6M
Settlement Date2026-05-15
Financial Health
Current Ratio?6.75Strong
Quick Ratio?4.94Strong
Cash Ratio?0.94Adequate
Debt/Equity?1.09Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score75/100
P/E?N/A▾
P/B?3.28FAIR▾
Peers100
S&P52
P/S?3.83FAIR▾
Peers100
S&P40
P/FCF?N/A▾
EV/EBITDA?-26.9CHEAP▾
Peers100
S&P97
EV/Sales?4.75FAIR▾
Peers100
S&P38
Returns & Efficiency
ROE?-29.4%WEAK▾
Peers50
S&P6
ROA?-12.6%WEAK▾
Peers50
S&P3
Cash Flow & Enterprise
FCF?$-126297000
Enterprise Value?$931.3M
Fundamentals ratios updated end of day